VEGf165 mediates glomerular endothelial repair

Journal of Clinical Investigation

Volumn 104, Issue 7, 1999, Pages 913-923

  Ostendorf, Tammo ^a   Kunter, Uta ^a   Eitner, Frank ^b   Loos, Anneke ^a   Regele, Heinz ^c   Kerjaschki, Dontscho ^c   Henninger, Dwight D ^d,e   Janjic, Nebojsa ^d   Floege, Jürgen ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d GILEAD SCIENCES   (United States)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ISOPROTEIN; PUROMYCIN AMINONUCLEOSIDE; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; MACROGOL DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL ACTIVATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULUS EPITHELIUM; HEYMANN NEPHRITIS; HISTOPATHOLOGY; LEUKOCYTOSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; MICROANEURYSM; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; TISSUE REGENERATION; TISSUE REPAIR; ANEURYSM; ANGIOGENESIS; ANIMAL; CELL DIVISION; CORNEA; CYTOLOGY; DRUG EFFECT; GLOMERULONEPHRITIS; GLOMERULUS; HUMAN; KIDNEY CIRCULATION; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULARIZATION; WISTAR RAT;

ANEURYSM; ANIMALS; CELL DIVISION; CORNEA; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY GLOMERULUS; LYMPHOKINES; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; POLYETHYLENE GLYCOLS; PROTEIN ISOFORMS; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RENAL CIRCULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032589378     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6740     Document Type: Article

References (56)

1. Ballerman, B.J. 1997. Endothelial responses to immune injury. In Immunologic renal diseases. E.G. Neilson and W.G. Couser, editors. Lippincott-Raven Publishers, Philadelphia, PA. 627-654.
2. Rennke, H.G. 1988. Glomerular adaptations to renal injury or ablation. Role of capillary hypertension in the pathogenesis of progressive glomerulosclerosis. Blood Purif. 6:230-239.
3. Lee, L.K., Meyer, T.W., Pollock, A.S., and Lovett, D.H. 1995. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J. Clin. Invest. 96:953-964.
4. Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
5. Connolly, D.T. 1991. Vascular permeability factor: a unique regulator of blood vessel function. J. Cell. Biochem. 47:219-223.
6. Takahashi, T., Huynh-Do, U., and Daniel, T.O. 1998. Renal microvascular assembly and repair: power and promise of molecular definition. Kidney Int. 53:826-835.
7. Gibbons, G.H., and Dzau, V.J. 1994. The emerging concept of vascular remodeling. N. Engl. J. Med. 330:1431-1438.
8. Ferrara, N., Houck, K.A., Jakeman, L.B., Winer, J., and Leung, D.W. 1991. The vascular endothelial growth factor family of polypeptides. J. Cell. Biochem. 47:211-218.
9. Carmeliet, P., et al. 1999. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5:495-502.
10. Neufeld, G., Tessler, S., Gitay-Goren, H., Cohen, T., and Levi, B.Z. 1994. Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res. 5:89-97.
11. Simon, M., et al. 1995. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 268:F240-F250.
12. Noguchi, K., et al. 1998. Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9:1815-1825.
13. Monacci, W.T., Merrill, M.J., and Oldfield, E.H. 1993. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol. 264:C995-C1002.
14. Brown, L.F., et al. 1992. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 42:1457-1461.
15. Grone, H.J., Simon, M., and Grone, E.F. 1995. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J. Pathol. 177:259-267.
16. Iruela-Arispe, L., et al. 1995. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am. J. Pathol. 147:1715-1727.
17. Shulman, K., Rosen, S., Tognazzi, K., Manseau, E.J., and Brown, L.F. 1996. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 7:661-666.
18. Brown, L.F., et al. 1993. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143:1255-1262.
19. Schroppel, B., Huber, S., Horster, M., Schlondorff, D., and Kretzler, M. 1998. Analysis of mouse glomerular podocyte mRNA by single-cell reverse transcription-polymerase chain reaction. Kidney Int. 53:119-124.
20. Kretzler, M., et al. 1998. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int. Suppl. 67:S159-S161.
21. Houck, K.A., et al. 1991. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1806-1814.
22. Takahashi, T., et al. 1995. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem. Biophys. Res. Commun. 209:218-226.
23. Gruden, G., et al. 1997. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc. Natl. Acad. Sci. USA. 94:12112-12116.
24. Iijima, K., Yoshikawa, N., Connolly, D.T., and Nakamura, H. 1993. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 44:959-966.
25. Jakeman, L.B., Winer, J., Bennett, G.L., Altar, C.A., and Ferrara, N. 1992. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89:244-253.
26. Ruckman, J., et al. 1998. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273:20556-20567.
27. Breier, G., Albrecht, U., Sterrer, S., and Risau, W. 1992. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 114:521-532.
28. Floege, J., et al. 1999. A novel approach to specific growth factor inhibition in vivo: antagonism of PDGF in glomerulonephritis by aptamers. Am. J. Pathol. 154:169-179.
29. Salant, D.J., Darby, C., and Couser, W.G. 1980. Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J. Clin. Invest. 66:71-81.
30. Burg, M., Ostendorf, T., Mooney, A., Koch, K.M., and Floege, J. 1997. Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety. Lab. Invest. 76:505-516.
31. Canaan-Kuhl, S., Ostendorf, T., Zander, K., Koch, K.M., and Floege, J. 1998. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int. 53:1143-1151.
32. Frankfurt, O.S., Robb, J.A., Sugarbaker, E.V., and Villa, L. 1996. Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp. Cell Res. 226:387-397.
33. Baker, A.J., et al. 1994. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J. Clin. Invest. 94:2105-2116.
34. Poelstra, K., Hardonk, M.J., Koudstaal, J., and Bakker, W.W. 1990. Intraglomerular platelet aggregation and experimental glomerulonephritis. Kidney Int. 37:1500-1508.
35. Johnson, R.J., Garcia, R.L., Pritzl, P., and Alpers, C.E. 1990. Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am. J. Pathol. 136:369-374.
36. Yamamoto, T., and Wilson, C.B. 1987. Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int. 32:514-525.
37. Johnson, R.J., et al. 1991. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J. Clin. Invest. 87:847-858.
38. Yoshimura, A., et al. 1991. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 40:470-476.
39. Iida, H., et al. 1991. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc. Natl. Acad. Sci. USA. 88:6560-6564.
40. Floege, J., et al. 1991. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 40:477-488.
41. Floege, J., et al. 1998. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 9:792-801.
42. Bell, C., Lynam, E., Landfair, D.J., Janjic, N., and Wiles, M.E. 1999. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell. Dev. Biol. In press.
43. Pabst, R., and Sterzel, R.B. 1983. Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int. 24:626-631.
44. Uchida, K., et al. 1994. Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor. Am. J. Physiol. 266:F81-F88.
45. Roberts, W.G., and Palade, G.E. 1995. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108:2369-2379.
46. Gerber, H.P., et al. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-30343.
47. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-1028.
48. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165.
49. Floege, J., Eng, E., Young, B.A., Couser, W.G., and Johnson, R.J. 1993. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int. 43:369-380.
50. Johnson, R.J., et al. 1992. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J. Exp. Med. 175:1413-1416.
51. Trachtman, H., Futterweit, S., Franki, N., and Singhal, P.C. 1998. Effect of vascular endothelial growth factor on nitric oxide production by cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 245:443-446.
52. Clauss, M., et al. 1990. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172:1535-1545.
53. Klanke, B., et al. 1998. Effects of vascular endothelial growth factor (VEGF)/vascular permeability facror (VPF) on haemodynamics and permselectivity of the isolared perfused rat kidney. Nephrol. Dial. Transplant. 13:875-885.
54. Malavaud, B., et al. 1997. Activation of Flk-1/KDR mediates angiogenesis but not hypotension. Cardiovasc. Res. 36:276-281.
55. Darland, D.C., and D'Amore, P.A. 1999. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 103:157-158.
56. Gerber, H.P., et al. 1999. VEGF is required for growth and survival in neonatal mice. Development. 126:1149-1159.